The EPSRC Centre for Doctoral Training in Statistics and Machine Learning (StatML) will address the EPSRC research priority of the 'physical and mathematical sciences powerhouse' through an innovative cohort-based training program. StatML harnesses the combined strengths of Imperial and Oxford, two world-leading institutions in statistics and machine learning, in collaboration with a broad spectrum of industry partners, to nurture the next generation of leaders in this field. Our students will be at the forefront of advancing the core methodologies of data science and AI, crucial for unlocking the value inherent in data to benefit industry and society. They will be equipped with advanced research, technical, and practical skills, enabling them to make tangible real-world impacts. Our students will be ethical and responsible innovators, championing reproducible research and open science. Collaborating with students, charities and equality experts, StatML will also pioneer a comprehensive strategy to promote inclusivity, attract individuals from diverse backgrounds and eliminate biases. This will help diversify the UK's future statistics and machine learning workforce, essential for ensuring data science is used for public good. Data science and AI are now part of our everyday lives, transforming all sectors of the economy. To future-proof the UK's prosperity and security, it is essential to develop new methodology, specifically tailored to meet the big societal challenges of the future. The techniques underpinning such methods are founded in statistics and machine learning. Through close collaboration with a broad range of industry partners, our cohort-based training will support the UK in producing a critical mass of world-leading researchers with expertise in developing cutting-edge, impactful statistical and machine learning methodology and theory. It is well documented in government and learned society reports that the UK economy has an urgent need for these people. The significant level of industry support for our proposal also highlights the necessity of filling this gap in the UK data science ecosystem. StatML will learn from and build upon our previous successful experiences in cohort training of doctoral students (our existing StatML CDT funded in 2018, as well as other CDTs at Imperial and Oxford). Our students will continue to produce impactful, internationally leading research in statistics and machine learning (as evidenced by our students' impressive publication record and our world-leading research environment, as rated by the REF 2021 evaluation), while complementing this with a bespoke cohort-based Advanced Training program in Statistics and Machine Learning (StatML-AT). StatML-AT has been developed from our experience and in partnership with industry. It will be responsive to emerging technologies and equip our students with the practical skills required to transform how data is used. It will be delivered by our outstanding academics from both institutions alongside with industry leaders to ensure that students receive training in cutting edge technologies, along with the latest ideas in ethics, responsible innovation, sustainability and entrepreneurship. This will be complemented by industrial and academic placements to allow the students to develop their own international network and produce high-impact research. Together, StatML and its partners will train 90+ students over 5 cohorts. More than half of these will be funded from external sources, including 25+ by industry, representing excellent value for money. Our diverse cohorts will benefit from a unique and responsive training program combining academic excellence, industry engagement, and interdisciplinary culture. This will make StatML a vibrant research environment inspiring the next methodological advancements to transform the use of data and AI across industry and society.

In a landmark study involving 12,456 male patients diagnosed with colorectal cancer, those who took Sildenafil (marketed as Viagra) after diagnosis had over twice the odds of survivng for 10 years than those who did not. Sildenafil is commonly prescribed for erectile dysfunction and pulmonary arterial hypertension and acts by widening blood vessels (vasodilation). We propose that this drug influences colorectal cancer outcomes via two mechanisms: a) increasing the diameter of small vessels which inhibits tumour cell occlusion, a key step in metastasis progression and b) modification of the permeability and architecture of blood vessels, which may assist drug and immune cell delivery to tumours (Fig. 1). We will explore these hypothesis via 3 key aims: 1) development of a microvascular microfluidic platform that incorporates vasodilation induced by precapillary sphincter contraction, 2) investigate how vasodilation-mediated hemodynamic resistance influences tumour cell entrapment, invasion and metastasis formation, 3) explore the influence of endothelial permeability and microvascular normalisation on the tumour penetration and distribution of antibody therapeutics and immune cell infiltration & activity in microfluidic & mice models. Vasodilator drugs have long track records of safe use in humans and an understanding of how this drug influences cancer outcomes via the vasculature may provide a pathway to develop next generation vasodilator adjuvants without unwanted side effects for patients with cancer.

Chemical biology is spearheading the development & translation of novel molecular tools and technologies to study biology and develop biomedical understanding. Dovetailing these platforms with industry 4.0/5.0 breakthroughs in automation & robotics, artificial intelligence & machine learning, the CDT will unlock the Lab of the Future paradigm. This will redefine the state of the art with respect to making, measuring, modelling & manipulating molecular interactions in biological systems, leading to novel R&D workflows, promoting efficient design-test cycles and driving sustainability. These molecular technologies will (i) enable biological & medical research, (ii) revolutionise understanding of disease & (iii) create novel diagnostics, drugs & therapies, focusing increasingly on individual patient outcomes. They will also impact the agri-tech sector which faces huge demand to increase productivity by unlocking strategies to e.g. track agrochemicals in plants/soil, understand modes of action & drive precision farming. Similarly, advances in personal care industrial processes are critically dependent on development of molecular technologies to gain insight into structured product design. The application of novel molecular tools/technologies, Lab of the Future strategies & their commercialisation through the instrumentation science sector is thus critical to the UK economy, supporting >4,500 healthcare, personal care, agri-science & biotech companies. This will transform (i) therapeutic, agrochemical & personal care product discovery (ii) med-tech/biotech/healthcare instrumentation R&D pipelines & (iii) stimulate creation of SMEs. Working closely with civic partners including Hammersmith & Fulham Council and the NHS, the CDT's talent & research pipeline will act as a growth engine for one of the most rapidly expanding Life Science ecosystems in Europe, the White City Innovation District. Given the importance of Chemical Biology to UK plc there is great demand but short supply of Chemical Biology PhD graduates able to match the pace of innovation across the physical/life science interface, at a time when industry & health sectors need these skills to accelerate productivity. The CDT in Chemical Biology: Empowering UK BioTech innovation with its unique 5 year programme: 1 year MRes + 3 year PhD + 1 year ELEVATE Fellowship directly addresses this skills gap by training a new generation of career-ready graduates, able to embrace the Lab of the Future concept and unlock its potential by fusing innovative molecular tools & tech with industry 4.0 & 5.0 advances to study molecular interactions & develop applications in the life science, agriscience & personal care sectors. CDT students will benefit from a research and training programme created with >100 industry/external stakeholders designed to meet future employer's needs. Our cohort-based programme with EDI at its heart, will allow students to contextualise their work within wider CDT activities & find novel solutions to their research, supported by one of the world's largest Chemical Biology communities: the Institute of Chemical Biology (>165) research groups. Students will be trained in multidisciplinary blue skies/translational research, lean innovation, scale fast/fail fast approaches, creating scientists able to understand molecular technologies, sustainable product design, early-stage commercialisation, & industry's pace of change. To support this, our training includes Future Lab & HackEDU courses (prototyping training), a drug screening programme, Biz-Catalyst (entrepreneurial training), InnovaLab (SME accelerator), a Data Science course, Human Centred Design, Science Communication (with BBC) & Bioethics/RRI/Sustainability/Policy courses. Following PhD completion, students can enter the ELEVATE fellowship programme, bridging the gap between PhD & industry/academia, offering training, personalised workplace opportunities & enable students to kickstart new companies.